Reviewing CryoLife (CRY) & Its Competitors
CryoLife (NYSE: CRY) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its rivals? We will compare CryoLife to related companies based on the strength of its dividends, valuation, risk, institutional ownership, analyst recommendations, profitability and earnings.
Earnings and Valuation
This table compares CryoLife and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|CryoLife||$183.16 million||$23.56 million||68.79|
|CryoLife Competitors||$827.05 million||$159.46 million||33.79|
CryoLife’s rivals have higher revenue and earnings than CryoLife. CryoLife is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
68.9% of CryoLife shares are owned by institutional investors. Comparatively, 63.4% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 6.0% of CryoLife shares are owned by insiders. Comparatively, 13.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for CryoLife and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CryoLife presently has a consensus price target of $22.33, indicating a potential downside of 1.62%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 5.06%. Given CryoLife’s rivals higher possible upside, analysts clearly believe CryoLife has less favorable growth aspects than its rivals.
Volatility and Risk
CryoLife has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, CryoLife’s rivals have a beta of 1.08, suggesting that their average stock price is 8% more volatile than the S&P 500.
This table compares CryoLife and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
CryoLife beats its rivals on 7 of the 13 factors compared.
CryoLife Company Profile
CryoLife, Inc. (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc. valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix. PhotoFix is a pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde. The Preservation Services segment includes external services, such as preservation of cardiac and vascular tissues. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch, both of which are processed using CryoLife’s SynerGraft technology.
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.